Dedicated to pipeline expansion in immuno-oncology, Janssen Biotech (a division of Johnson & Johnson) has entered into a definitive agreement to acquire the oncolytic virus company, BeneVir Biopharm, for a sum of US$1.04 B. BeneVir’s T-StealthTM oncolytic virus platform engineers oncolytic viruses to overcome the body’s immune barrier and complements the in-house immuno-oncology research of Janssen. This deal marks the increasing focus on oncolytic viral immunotherapies and follows recent deal announcements in this space from Merck & Co and AbbVie.